Berlin, Germany: Oral administration of synthetic THC capsules (dronabinol) mitigates symptoms in patients with treatment-resistance obsessive compulsive disorder (OCD), according to a pair of case studies published in the April issue of the American Journal of Psychiatry.
Investigators at Berlin's University of Medicine, Department of Psychiatry and Psychotherapy, reported two cases of OCD patients augmenting their treatment regimens with oral THC.
For the first patient, a 38-year-old female, dronabinol administration three times daily significantly decreased OCD symptoms within ten days. For the second patient, a 36-year-old male, dronabinol treatment twice daily significantly decreased symptoms of OCD within two weeks.
Neither patient reported any physical or mental health side-effects from dronabinol.
Prior to their use of oral THC, both patients had been unresponsive to standard treatment medications.
For more information, please contact Paul Armentano, NORML Deputy Director, at: email@example.com. Full text of the case study, “Improvement in refractory obsessive compulsive disorder with dronabinol,” appears online in the American Journal of Psychiatry at: http://ajp.psychiatryonline.org/cgi/content/full/165/4/536.